Getein Biotech Inc (SHG:603387) — Market Cap & Net Worth
Market Cap & Net Worth: Getein Biotech Inc (603387)
Getein Biotech Inc (SHG:603387) has a market capitalization of $699.08 Million (CN¥4.78 Billion) as of September 21, 2026. Listed on the SHG stock exchange, this China-based company holds position #10666 globally and #2910 in its home market, demonstrating a 2.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Getein Biotech Inc's stock price CN¥9.42 by its total outstanding shares 507153517 (507.15 Million). Also see total assets of Getein Biotech Inc for a full breakdown of the balance sheet.
Getein Biotech Inc Market Cap History: 2017 to 2026
Getein Biotech Inc's market capitalization history from 2017 to 2026. Data shows growth from $1.05 Billion to $699.08 Million (2.44% CAGR). Also see Getein Biotech Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Getein Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Getein Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Getein Biotech Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.59x
Getein Biotech Inc's market cap is 0.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.81x
Getein Biotech Inc's market cap is 2.81 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.05 Billion | $488.58 Million | $193.99 Million | 2.15x | 5.41x |
| 2018 | $655.44 Million | $686.24 Million | $249.61 Million | 0.96x | 2.63x |
| 2019 | $808.82 Million | $968.20 Million | $339.67 Million | 0.84x | 2.38x |
| 2020 | $1.22 Billion | $1.12 Billion | $304.73 Million | 1.08x | 3.99x |
| 2021 | $1.01 Billion | $1.40 Billion | $398.99 Million | 0.72x | 2.54x |
| 2022 | $907.15 Million | $1.82 Billion | $498.91 Million | 0.50x | 1.82x |
| 2023 | $816.34 Million | $1.37 Billion | $279.77 Million | 0.60x | 2.92x |
| 2024 | $612.25 Million | $1.16 Billion | $223.64 Million | 0.53x | 2.74x |
| 2025 | $621.16 Million | $1.05 Billion | $220.66 Million | 0.59x | 2.81x |
Competitor Companies of 603387 by Market Capitalization
Companies near Getein Biotech Inc in the global market cap rankings as of September 21, 2026. Review 603387 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Getein Biotech Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Getein Biotech Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Getein Biotech Inc's market cap moved from $1.05 Billion to $ 699.08 Million, with a yearly change of 2.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥699.08 Million | +12.54% |
| 2025 | CN¥621.16 Million | +1.45% |
| 2024 | CN¥612.25 Million | -25.00% |
| 2023 | CN¥816.34 Million | -10.01% |
| 2022 | CN¥907.15 Million | -10.59% |
| 2021 | CN¥1.01 Billion | -16.62% |
| 2020 | CN¥1.22 Billion | +50.45% |
| 2019 | CN¥808.82 Million | +23.40% |
| 2018 | CN¥655.44 Million | -37.50% |
| 2017 | CN¥1.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 21st, 2026 the market cap of Getein Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $699.08 Million USD |
| MoneyControl | $699.08 Million USD |
| MarketWatch | $699.08 Million USD |
| marketcap.company | $699.08 Million USD |
| Reuters | $699.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Getein Biotech Inc
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical … Read more